The Liquid Embolics Market is expected to grow manifold in the upcoming period. With technological advancements like ML and AI being incorporated in abundance, the healthcare vertical is likely to reach the top pedestal in the years to come. There are Bluetooth-operated health monitors, which let doctors receive precise information, that too, from time to time.
The global liquid embolic market was valued at US$ 231.9 Mn in 2020, and is expected to exhibit a CAGR of around 8.9% over the forecast period (2021-2031).
Embolization is a procedure that uses certain particles such as tiny gelatine sponges or beads to inhibit blood vessels. The embolization process is used to stop bleeding or inhibit the flow of blood to a tumour or an abnormal area of tissue. Tumor embolization, thus, is a process that is used for treating tumors by blocking blood supply to the tumor cells.
Availability of effective conventional, first-level therapies for the treatment of liver cancer, uterine fibroids, hemorrhagic stroke, and other hemorrhagic conditions is a key driver for market growth. Therapies such as surgery, chemotherapy, and radiation therapy are preferred options in cancer treatment.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/25513
Liquid embolic therapy has shown to be safe and effective with high success rate and less post-operative complications. Commercially available liquid embolics have been used to successfully treat hypervascular tumors, peripheral vascular lesions, and varicoceles.
According to Globocan, around 19.3 million cases of cancer were detected in 2020 globally. On the other hand, as per data published by Cancer.Net in 2021, liver cancer is the fifth-most-common cancer in men and the ninth-most-common in women. Rising prevalence of cancer and tumors such as brain tumor will drive demand for liquid embolics over the coming years.
Company Profiles:
- Medtronic
- Meril Life Sciences Pvt Ltd.
- Johnson & Johnson
- Microvention Inc.
- Terumo Corporation
- Guerbet
- Emboflu
Request for Methodology@ https://www.persistencemarketresearch.com/methodology/25513
Key Takeaways from Market Study
- Liquid embolic vials, owing to their effectiveness in the storage of large volumes of liquid and ease of use, continue to hold the largest market. This product segment is expected to experience a CAGR of 9.6% through 2031.
- Based on indication, brain arterio-venous malformations (bAVM) is leading with over 44% of market share.
- Hospitals will dominate the liquid embolic market with a market share of nearly 60%.
- By region, North America is slated to dominate the global market for liquid embolics with over 1/3 market share, while experiencing twofold growth over the decade.
“Rising prevalence of tumours & cardiovascular diseases and new product launches & approvals are expected to drive market expansion over the coming years,” says an analyst of Persistence Market Research.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/25513
Who is Winning?
Key market players such as Medtronic and Terumo, amongst others, are focusing on expansion in emerging regions by manufacturing and introducing new product lines in their already existing product portfolios.
- OptiSphere embolization spheres launched in the U.S. by Medtronic (2018) is providing new treatment options for embolization of hypervascular tumours.
- Launch of an intravascular aneurysm treatment device called WEB™ Embolization System in Japan by Terumo Corporation (2020).
Prominent liquid embolic product manufacturers include Medtronic, Meril Life Sciences Pvt. Ltd., Johnson & Johnson, Microvention Inc., Guerbet, and Emboflu.
What Does the Report Cover?
Persistence Market Research offers a unique perspective and actionable insights on the liquid embolic market in its latest study, presenting a historical demand assessment of 2016 – 2020 and projections for 2021 – 2031.
The research study is based on the product (liquid embolic vials and liquid embolic prefilled injectables), indication (brain arterio-venous malformations, tumour embolization, radiology, and cardiology), and end user (hospitals, ambulatory surgical centers, and independent speciality centers), across seven key regions of the world.
About Us:
Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com